Skip to main content
SpringerLink
Log in
Book cover

Regional Cancer Therapy pp 269–282Cite as

Regional Therapy for Peritoneal Surface Malignancy

  • Chapter

  • 979 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Carcinomatosis has been in the past a universally fatal manifestation of gastrointestinal cancer. It has also carried a nearly lethal prognosis in ovarian cancer. It remains the major site of treatment failure with these diseases. A review of the natural history of carcinomatosis from the world literature was undertaken. The rationale, technology, and results of treatment using peritonectomy and perioperative intraperitoneal chemotherapy represents an essential part of the treatment. Small-volume residual disease must be treatedby chemotherapy and hyperthermia. To apply these treatments properly, selection of patients using prognostic indicators is necessary. The results of treating patients who have peritoneal mesothelioma, pseudomyxoma peritonei, and carcinomatosis from colorectal cancer indicate that progress in the curative management of carcinomatosis has been made. Peritoneal surface dissemination of cancer can no longer be equated with a terminal condition. A multidisciplinary approach to treatment employing surgery and regional chemotherapy has created a new standard of care for this pattern of cancer dissemination.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sampson J. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol 1931;7:423–443.

    CAS  PubMed  Google Scholar 

  2. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multi-centric prospective study. Cancer 2000;88:358–363.

    Article  PubMed  CAS  Google Scholar 

  3. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002;94:492–499.

    Article  PubMed  CAS  Google Scholar 

  4. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001;37:979–984.

    Article  PubMed  CAS  Google Scholar 

  5. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999;6:645–650.

    Article  PubMed  CAS  Google Scholar 

  6. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am 2003;12:703–727.

    Article  Google Scholar 

  7. Eltabbakh GH, Werness BA, Piver S, Blumenson LE. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 1998;71:230–239.

    Article  PubMed  CAS  Google Scholar 

  8. Mohamed F, Sugarbaker PH. Peritoneal mesothelioma. Curr Treat Options Oncol 2002;3:375–386.

    Article  PubMed  Google Scholar 

  9. Wirtzfed DA, Rodriguez-Bigas M, Weber T, Petrelli NJ. Disseminated peritoneal adenomucinosis: a critical review. Ann Surg Oncol 1999;:797–801.

    Google Scholar 

  10. Weiss L. Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells, in Peritoneal Carcinomatosis: Principles of Management (Sugarbaker PH, ed.), Boston: Kluwer Academic; 1996:1–12.

    Google Scholar 

  11. Weiss L. Metastatic inefficiency: intravasculat and intraperitoneal implantation of cancer cells. Cancer Treat Res 1996;82:1–12.

    PubMed  CAS  Google Scholar 

  12. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trend Cell Biol 2001;11:537–543.

    Google Scholar 

  13. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001;70:478–490.

    PubMed  CAS  Google Scholar 

  14. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg 1999;384:576–587.

    Article  PubMed  CAS  Google Scholar 

  15. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanism of the patterns of spread. Metastases Rev 2003;22:465–472.

    Article  Google Scholar 

  16. Sugarbaker PH. Total gastrectomy with diverting jejunoseomy for complete cytoreduction of 36 patients with pseudomyxoma peritonei syndrome. Br J Surg 2002;89:208–212.

    PubMed  CAS  Google Scholar 

  17. Sugarbaker PH. Laser-mode electrosurgery, in Peritoneal Xarcinomatosis: Principles of Management (Sugarbaker PH, ed.), Boston: Kluwer, 1996:375–385.

    Google Scholar 

  18. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier, in Peritoneal Carcinomatosis: Principles of Management (Sugarbaker PH, ed.), Boston: Kluwer, 1996:53–63.

    Google Scholar 

  19. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12(3 suppl4):1–6.

    PubMed  CAS  Google Scholar 

  20. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol 1985;248(3 pt 2):F425–435.

    PubMed  CAS  Google Scholar 

  21. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1–11.

    PubMed  CAS  Google Scholar 

  22. Armour EP, McEachern D, Wang Z, Cony PM, Martinez A. Sensitivity of human cells to mild hyperthermia. Cancer Res 1993;53:2740–2744.

    PubMed  CAS  Google Scholar 

  23. Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991;27:472–477.

    Article  PubMed  CAS  Google Scholar 

  24. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33–56.

    Article  PubMed  Google Scholar 

  25. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:33–56.

    Article  Google Scholar 

  26. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis, in Peritoneal Carcinomatosis: Principles of Management (Sugarbaker PH, ed.), Boston: Kluwer Acadenic, 1996:359–374.

    Google Scholar 

  27. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49–58.

    Google Scholar 

  28. Shridhar KS, Doria R, Raub WA Jr, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70:2969–2979.

    Article  Google Scholar 

  29. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in aregistry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147–153.

    PubMed  CAS  Google Scholar 

  30. Ascensio JA, Goldblatt P, Thomford NR. Primary malignant peritoneal mesotheliomas. A report of seven cases and a review of the litrature. Arch Surg 1990;125:477–481.

    Google Scholar 

  31. Wagner JC, Sleegs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260–271.

    PubMed  CAS  Google Scholar 

  32. Acherman YIZ, Welch LS, Bromley CM Sugarbaker PH. Clinical presentation of mesothelioma. Tumori 2003;89:269–273.

    PubMed  Google Scholar 

  33. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–621.

    Article  Google Scholar 

  34. Alcorn KW, Yan H, Shmookler BM, et al. Differential diagnosis of the simultaneous occurrence of colon carcinoma and peritoneal mesothelioma by immunohistichemistry. Surg Rounds 2000;23: 411–417.

    Google Scholar 

  35. Jacquet P, Sugarbaker PH. Influence of wound healing on gastrointestinal cancer recurrence. Wounds 1995;7:40–47.

    Google Scholar 

  36. Fann JI, Vierra M, Fisher D, et al. Pseudomyxomaperitonei. SurgGynecol Obstet 1993;177:441–447.

    CAS  Google Scholar 

  37. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998;85:1332–1339.

    Article  PubMed  CAS  Google Scholar 

  38. Sherer DM, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature. Gynecol Obstet Invest 2001;51:73–80.

    Article  PubMed  CAS  Google Scholar 

  39. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonii syndrome. Adv Surg 1997;30:233–280.

    Google Scholar 

  40. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucunosis and peritoneal mucinous carcinomatosis. Am J Surg Path 1995;19:1390–1408.

    PubMed  CAS  Google Scholar 

  41. Sugarbaker PH. Pseudomyxomaperitonei: a cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994;219:109–111.

    Article  PubMed  CAS  Google Scholar 

  42. Sugarbaker PH, Chang D. Result of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–731.

    Article  PubMed  CAS  Google Scholar 

  43. Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis, in Peritoneal Carcinomatosis: Principles of Management (Sugarbaker PH, ed.), Boston: Kluwer, 1996:263–288.

    Google Scholar 

  44. Jacquet P, Jelinek J, Sugarbaker PH. Abdominal computed tomographic scan in the selection of patients with nucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 1995; 181:530–538.

    PubMed  CAS  Google Scholar 

  45. Sugarbaker PH. Intraperitoneal Chemotherapy and Cytoreductive Surgery: Manual for Physicians and Nurses, 3rd ed. Grand Rapids, MI: Ludann, 1998.

    Google Scholar 

  46. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthrmic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11:393–398.

    Article  PubMed  Google Scholar 

  47. Guner Z, Schmidt U, Dahlke MH, et al. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Coloretal Dis 2005;20:155–160.

    Article  CAS  Google Scholar 

  48. Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005;48:1372–1379.

    Article  PubMed  Google Scholar 

  49. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2006;50:37–42.

    Article  Google Scholar 

  50. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthrmic intraperitoneal chemotherapy. Ann Surg 2007; 245:104–109.

    Article  PubMed  Google Scholar 

  51. Stewart JH 4th, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgry and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13:624–634.

    Article  PubMed  Google Scholar 

  52. Dawson LE, Russell AH, Tong D, et al. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical pattern of recurrence following surgery alone. J Surg Oncol 1983;22:95–99.

    Article  PubMed  CAS  Google Scholar 

  53. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989;63:364–367.

    Article  PubMed  CAS  Google Scholar 

  54. Glehen O, Gilly FN, Sugarbaker PH. New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis? Scand J Surg 2003;92:178–179.

    PubMed  CAS  Google Scholar 

  55. Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–3743.

    Article  PubMed  Google Scholar 

  56. Glehen O, Kwiatkowsky F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–3292.

    Article  PubMed  CAS  Google Scholar 

  57. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545–1550.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington Cancer Institute, Washington Hospital Center, Washington, DC

    Yehuda Skornick MD & Paul H. Sugarbaker MD

Authors
  1. Yehuda Skornick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul H. Sugarbaker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

  2. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) & Ulrike Stein PhD (Assistant Professor) (Professor and Head of Surgical Oncology) &  (Assistant Professor)

  3. Tumor Metastasis and Therapy Response Program, Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Ulrike Stein PhD (Assistant Professor) (Assistant Professor)

  4. Erasmus University MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Alexander M. M. Eggermont MD, PhD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Skornick, Y., Sugarbaker, P.H. (2007). Regional Therapy for Peritoneal Surface Malignancy. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-225-0_15

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-672-6

  • Online ISBN: 978-1-59745-225-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation